ENANTA PHARMACEUTICALS INCENTAEarnings & Financial Report
Nasdaq
NextMay 14, 2026
ENTA Q1 2026 Key Financial Metrics
Revenue
$18.6M
Gross Profit
N/A
Operating Profit
$-11.3M
Net Profit
$-11.9M
Gross Margin
N/A
Operating Margin
-60.5%
Net Margin
-64.1%
YoY Growth
9.8%
EPS
$-0.42
Financial Flow
ENANTA PHARMACEUTICALS INC Q1 2026 Financial Summary
ENANTA PHARMACEUTICALS INC reported revenue of $18.6M for Q1 2026, with a net profit of $-11.9M (-64.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $18.6M |
|---|---|
| Net Profit | $-11.9M |
| Gross Margin | N/A |
| Operating Margin | -60.5% |
| Report Period | Q1 2026 |
ENANTA PHARMACEUTICALS INC Annual Revenue by Year
ENANTA PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $65.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $65.3M |
| 2024 | $67.6M |
| 2023 | $79.2M |
| 2022 | $86.2M |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.1M | $18.0M | $14.6M | $17.0M | $14.9M | $18.3M | $15.1M | $18.6M |
| YoY Growth | -4.2% | -4.9% | -22.8% | -5.8% | -12.5% | 1.9% | 3.5% | 9.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $413.6M | $398.8M | $376.7M | $348.6M | $323.0M | $301.0M | $280.7M | $329.5M |
| Liabilities | $247.4M | $249.9M | $247.8M | $236.8M | $229.5M | $221.8M | $216.0M | $202.9M |
| Equity | $166.1M | $148.9M | $128.8M | $111.8M | $93.5M | $79.3M | $64.7M | $126.6M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-28.6M | $-14.8M | $-10.4M | $-16.8M | $-13.5M | $17.5M | $-6.5M | $-11.7M |